3 hours Inozyme Pharma (NASDAQ:INZY) Given “Buy” Rating at Needham & Company LLCMarketBeat
Needham & Company LLC reissued a “buy” rating and issued a $23.00 price objective on shares of Inozyme Pharma in a report on Friday.
XNeedham & Company LLC reissued a “buy” rating and issued a $23.00 price objective on shares of Inozyme Pharma in a report on Friday.
X